ROXANE LABORATORIES, INC. ANNOUNCES NEW RISK EVALUATION AND MITIGATION STRATEGIES (REMS) WEBSITE CONTENT ON WWW.ROXANE.COM

COLUMBUS, OH – September 12, 2012 –Right Now at Roxane Laboratories, patient and community safety is our highest priority. We support the work of physicians, pharmacists, and other healthcare providers nationwide through our participation in Risk Evaluation and Mitigation Strategies (REMS) programs. Above all, Roxane is committed to ensuring appropriate and safe use of all our products.

On September 12, 2012 a new section of www.Roxane.com will be dedicated to Risk Evaluation and Mitigation Strategies (REMS) programs. It contains information about REMS programs including what they are, what is a medication guide, what they consist of, and what this means for patients. It will also help you quickly identify which Roxane Laboratories products are subject to REMS, and provide quick links to the Full Prescribing Information complete with REMS Medication Guides. Please take a moment to check it out!

About Roxane Laboratories, Inc.
Roxane Laboratories is located in Columbus, OH in a modern 500,000 square foot manufacturing and laboratory facility. The facility spans 70 acres and currently employs over 1,000 people. Currently, Roxane Laboratories markets over 80 medications in nearly 250 package sizes, focusing on an expanding line of Multisource pharmaceutical products including: bulk and unit-dose liquids and solids; coated, sustained-release and controlled-release tablets; nasal sprays, cytotoxics and CII narcotics.

Roxane Laboratories, Inc., is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.

For more information, please visit http://www.Roxane.com.

About Boehringer Ingelheim Corporation
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates in 50 countries and more than 42,000 employees. Since its foundation in 1885, the family-owned company has been committed for more than 125 years to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

Today, Boehringer Ingelheim is one of the world’s leading companies for contract development and manufacture of biopharmaceuticals. All types of services from mammalian cell line or microbial strain development to final drug production can be delivered within a one-stop-shop concept. Boehringer Ingelheim delivers services for pre-clinical development up to global market supply with a strong commitment to its customers at its global manufacturing facilities for mammalian cell culture and microbial fermentation. Boehringer Ingelheim has brought 19 molecules to market and has many years of experience in multiple molecule classes such as monoclonal antibodies, recombinant proteins, interferons, enzymes, fusion molecules and plasmid DNA. Furthermore, hightiter platform technologies for new antibody mimetic formats such as scaffold proteins and antibody fragments are available for the manufacture of customer products.

For more information, please visit http://us.boehringer-ingelheim.com.